Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC–MS/MS and its application to a pharmacokinetics study
- 1 February 2016
- journal article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 1011, 215-222
- https://doi.org/10.1016/j.jchromb.2016.01.006
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81274148)
- Beijing Municipal Health System Special Funds of High-Level Medical Personnel Construction (2014-3-063)
This publication has 20 references indexed in Scilit:
- Gefitinib: a review of its use in adults with advanced non-small cell lung cancerTargeted Oncology, 2015
- Metabolism considerations for kinase inhibitors in cancer treatmentExpert Opinion on Drug Metabolism & Toxicology, 2010
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometryJournal of Chromatography A, 2005
- Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2005
- Cytochrome P450-dependent metabolism of gefitinibXenobiotica, 2005
- United States Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2004
- Determination of Gefitinib in Plasma by Liquid Chromatography with a C12 Column and Electrospray Tandem Mass Spectrometry DetectionJournal of Liquid Chromatography & Related Technologies, 2004
- A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trialsJournal of Pharmaceutical and Biomedical Analysis, 2002